Protocol to establish a lung adenocarcinoma immunotherapy allograft mouse model with FACS and immunofluorescence-based analysis of tumor response

• Published in: STAR protocols Vol. 2; no. 2; p. 100595
• Main Authors: Peng, Zhengxin, Yu, Man, Lin, Jiaming, Dong, Tianqi, Zhang, Xiao, Shi, Mingjun, Qin, Min, Li, Shasha, Guo, Wencong, Zhang, Huixia, Sun, Shuguo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 18.06.2021; Elsevier
• Subjects: Cancer; Cell biology; Cell culture; Cell isolation; Flow cytometry/mass cytometry; Immunology; Microscopy; Model organisms; Protocol; Cell culture; Immunology; Microscopy; Cell biology; Model organisms; Cell isolation; Flow cytometry/mass cytometry; Cancer
• ISSN: 2666-1667; 2666-1667
• DOI: 10.1016/j.xpro.2021.100595

Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung cancer mouse model, anti-PD-1 treatment, tumor-infiltrating lymphocyte isolation, immunofluorescence, and flow cytometry analysis. This protocol can also be applied to other cancer types and immunotherapies. For complete details on the use and execution of this protocol, please refer to Yu et al. (2021) [Display omitted] •Establish a tumor-derived cell line from a genetic engineered lung cancer mouse model•Evaluate the tumor response to immunotherapy using an allograft lung cancer model•Isolate tumor-infiltrating lymphocytes from fresh tumor samples•Evaluate activity of lymphocytes by flow cytometry and infiltration by immunofluorescence Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung cancer mouse model, anti-PD-1 treatment, tumor-infiltrating lymphocyte isolation, immunofluorescence, and flow cytometry analysis. This protocol can also be applied to other cancer types and immunotherapies.